[1]Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatology, 2017, 66(1): 209-219. [2]Arroyo V, Moreau R, Jalan R, et al. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis. J Hepatol, 2015, 62(1): S131-S143. [3]Nafady-Hego H, Elgendy H, Nafady A, et al. Outcome of hepatitis b virus infection after living-donor liver transplant: a single-center experience over 20 years. Exp Clin Transplant, 2016, 14(2): 207-214. [4]王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3): 389-400. [5]中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171. [6]Machicao V I. Model for end-stage liver disease-sodium score: the evolution in the prioritization of liver transplantation. Clin Liver Dis, 2017, 21(2): 275-287. [7]Roberts JA, Ma B, Tredway LP, et al. Identification and pathogenicity of bacteria associated with etiolation and decline of creeping bentgrass golf course putting greens. Phytopathology, 2018, 108(1): 23-30. [8]李晓东, 徐东平. HBV相关慢加急性肝衰竭免疫病理发病机制研究进展. 实用肝脏病杂志, 2015, 18(3): 317-320. [9]Sobala-Szczygiel B, Boron-Kaczmarska A, Kepa L, et al. Acute liver failure during treatment of interferon alpha 2a chronic hepatitis b and coinfection of parvovirus b19. Przegl Epidemiol, 2016, 70(3): 444-448. [10]Gao S, Joshi SS, Osiowy C, et al. Chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants. Virol J, 2017, 14(1): 203. [11]Fujiwara K, Yasui S, Haga Y, et al. Early combination therapy with corticosteroid and nucleoside analogue induces rapid resolution of inflammation in acute liver failure due to transient hepatitis B virus infection. Intern Med, 2018, 57(11): 1543-1552. [12]Yu X, Zheng Y, Deng Y, et al. Serum interleukin (il)-9 and il-10, but not T-helper 9 (th9) cells, are associated with survival of patients with acute-on-chronic hepatitis b liver failure. Medicine (Baltimore), 2016, 95(16): e3405. [13]Huang C, Yu KK, Zheng JM, et al. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: a 10-year cohort study in a university hospital in east China. J Dig Dis, 2019, 20(1): 38-44. [14]Han Y, Gu L, Liu J, et al. Association of mutations in toll-like receptor 2 signaling genes with fulminant form of hepatitis B-related acute liver failure. J Infect Dis, 2017, 215(8): 1221-1230. [15]Zhao Q, Wu C S, Fang Y, et al. Glucocorticoid regulates nlrp3 in acute-on-chronic hepatitis B liver failure. Int J Med Sci, 2019, 16(3): 461-469. [16]Bockmann JH, Dandri M, Luth S, et al. Combined glucocorticoid and antiviral therapy of hepatitis b virus-related liver failure. World J Gastroenterol, 2015, 21(7): 2214-2219. [17]Hu J, Zhao H, Lou D, et al. Human cytomegalovirus and epstein-barr virus infections, risk factors, and their influence on the liver function of patients with acute-on-chronic liver failure. BMC Infect Dis, 2018, 18(1): 577. [18]Liu XR, Xu J, Wang YM, et al. The effects of paeoniflorin injection on soluble triggering receptor expressed on myeloid-1 (strem-1) levels in severe septic rats. Korean J Physiol Pharmacol, 2016, 20(6): 565-571. [19]葛文松, 范建高, 李光明. 小分子干扰RNA沉默高迁移率族蛋白B1抑制肝星状细胞Ⅰ型和Ⅲ型胶原合成. 实用肝脏病杂志, 2015, 18(4): 340-343. [20]Chen R, Zhu S, Fan X G, et al. High mobility group protein b1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology, 2018, 67(5): 1823-1841. [21]Yokoi T, Yokoyama Y, Kokuryo T, et al. Inhibition of Toll-like receptor 4 ameliorates experimental postischemic injury in the cholestatic liver through inhibition of high-mobility group box protein b1 (hmgb1) signaling. Surgery, 2018, 163(2): 270-276. |